Form 8-K - Current report:
SEC Accession No. 0000950170-24-110462
Filing Date
2024-10-01
Accepted
2024-09-30 17:37:53
Documents
13
Period of Report
2024-09-27
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K trvi-20240927.htm   iXBRL 8-K 50618
2 EX-99.1 trvi-ex99_1.htm EX-99.1 19585
3 GRAPHIC img251553556_0.jpg GRAPHIC 27075
  Complete submission text file 0000950170-24-110462.txt   234501

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT trvi-20240927.xsd EX-101.SCH 28464
15 EXTRACTED XBRL INSTANCE DOCUMENT trvi-20240927_htm.xml XML 4888
Mailing Address 195 CHURCH STREET 14TH FLOOR NEW HAVEN CT 06510
Business Address 195 CHURCH STREET 14TH FLOOR NEW HAVEN CT 06510 203-304-2499
Trevi Therapeutics, Inc. (Filer) CIK: 0001563880 (see all company filings)

EIN.: 450834299 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38886 | Film No.: 241340634
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)